BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Recursion Reports Encouraging Interim Phase 1 Data a Selective CDK7 Inhibitor

by Roman Kasianov   •   Dec. 9, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Clinical Trials   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Recursion (Nasdaq: RXRX) announced interim findings from the ongoing Phase 1/2 ELUCIDATE trial evaluating REC-617, a precision-designed, oral CDK7 inhibitor developed to address common resistance pathways in advanced solid tumors. The trial’s early results highlight a confirmed partial response in a heavily pre-treated patient and an overall favorable safety profile across multiple dose levels.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Although efficacy was not a primary endpoint in this early phase—nor typically expected at this stage—Recursion views the observed patient stability and response as promising given the heavily pre-treated population and preliminary nature of the data.

David Hallett, Ph.D., Chief Scientific Officer, Recursion:

“Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index. Using our precision design platform, we created a molecule with rapid oral absorption to reduce GI tissue exposure, a suitable half life to manage side effects, and target engagement covering the IC80 level.”

Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer, Recursion:

“These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population. Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year.”

Clinical Efficacy and Safety Highlights

  • A confirmed partial response (PR) by RECIST in a patient with platinum-resistant ovarian cancer who had received four prior lines of therapy; the response is ongoing after more than six months.
  • Four additional patients achieved stable disease (SD) for up to six months.
  • REC-617 showed a generally favorable safety profile with mostly Grade 1-2, on-target, reversible adverse events. No maximum tolerated dose (MTD) has been reached, and no discontinuations due to adverse events were reported.

REC-617 demonstrated dose-linear pharmacokinetics with rapid absorption and a half-life of approximately 5-6 hours. Early POLR2A modulation indicates around 80–90% target engagement, and twice-daily dosing is under investigation to potentially optimize clinical benefit.

Recursion plans to continue monotherapy dose escalation and initiate combination therapy studies in the first half of 2025. Additional data from ELUCIDATE and preclinical studies of REC-617 will be shared at future medical meetings.

See also: It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?

About ELUCIDATE

ELUCIDATE is a Phase 1/2, multicenter, open-label study evaluating REC-617 (GT Apeiron's, then Exscientia's GTAEXS617, prior to the Recursion-Exscientia merger in August 2024) as both a monotherapy and in combination with other treatments. The trial’s primary goals include assessing safety, pharmacokinetics, pharmacodynamics, and efficacy in advanced solid tumors, including NSCLC, colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, and head and neck cancer. Dose escalation in both monotherapy and combination settings aims to determine the optimal biological dose (OBD) before proceeding to the expansion phase.

Recursion Pharmaceuticals

Topics: Clinical Trials   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.